Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.

Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, Wightman DS, O'Leary MC, Millen LS, Leon MC, Briggs MA, Krishen A, Modell JG.

J Psychopharmacol. 2010 Apr;24(4):521-9. doi: 10.1177/0269881108100254. Epub 2009 Jan 22.

PMID:
19164492
2.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.

J Psychopharmacol. 2010 Aug;24(8):1209-16. doi: 10.1177/0269881109106953. Epub 2009 Nov 25.

PMID:
19939870
3.

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.

J Psychopharmacol. 2009 Jul;23(5):531-8. doi: 10.1177/0269881108089602. Epub 2008 Jul 17.

PMID:
18635695
4.

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA.

Clin Ther. 1999 Apr;21(4):643-58.

PMID:
10363731
5.

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA.

Clin Ther. 1998 May-Jun;20(3):505-16.

PMID:
9663366
6.

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD.

J Clin Psychiatry. 2003 Sep;64(9):1065-74.

PMID:
14628982
7.

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG.

J Clin Psychiatry. 2006 Jun;67(6):865-73.

PMID:
16848645
8.

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA.

J Clin Psychiatry. 2000 Mar;61(3):196-202.

PMID:
10817105
9.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
10.

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.

Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A.

Clin Ther. 2001 Jul;23(7):1040-58.

PMID:
11519769
11.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
12.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
13.

Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.

Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A.

J Clin Psychiatry. 2009 Jan;70(1):46-57. Epub 2008 Oct 7.

PMID:
19026248
14.

A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.

J Clin Psychopharmacol. 2006 Dec;26(6):653-6.

PMID:
17110825
16.
17.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.

Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA.

Int Clin Psychopharmacol. 2008 Sep;23(5):243-53. doi: 10.1097/YIC.0b013e32830cebed.

PMID:
18703933
18.

Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.

Safarinejad MR.

J Psychopharmacol. 2011 Mar;25(3):370-8. doi: 10.1177/0269881109351966. Epub 2010 Jan 15.

PMID:
20080928
19.

A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.

Fraguas R, da Silva Telles RM, Alves TC, Andrei AM, Rays J, Iosifescu DV, Wajngarten M.

Contemp Clin Trials. 2009 May;30(3):205-11. doi: 10.1016/j.cct.2009.01.007. Epub 2009 Jan 24.

PMID:
19470312

Supplemental Content

Support Center